Standard Life Private Equity Trust adds Dr. Dugald Agble and Yvonne Stillhart to its Board as Independent Directors

– UK, Edinburgh –  Standard Life Private Equity Trust plc (LON: SLPE) today announced the additions of Dr. Dugald Agble and Yvonne Stillhart to its Board as Independent Non-Executive Directors, with immediate effect.

“The Board regularly considers succession planning and is delighted to announce the appointment of Dugald and Yvonne. Both Dugald and Yvonne have extensive private experience and the Board looks forward to working with them.” said Board Chair, Christina McComb. 

About Dr. Dugald Agble

Dr. Dugald Agble holds a Ph.D. in Chemical Engineering from Imperial College London and has over 20 years of direct investment experience in Private Equity. He started his career at Nomura Principal Finance Group, which later evolved into Terra Firma Capital Partners. More recently, Dugald has been involved in investing in emerging and frontier markets at Helios Investment Partners and 8 Miles. Dugald is a Supervisory Board Member at FMO, the Dutch finance institution.

About Yvonne Stillhart

Yvonne Stillhart is an accomplished Board Director, Chair, and Board Committee Member (Audit & Risk, ESG, Finance) of private and public entities with technology and finance expertise. She has 30 years’ executive experience in business building and transformational leadership, governance, private equity and infrastructure investment, finance, banking, risk- and investment management across broad industries and geographical regions. She is a current director of EPE Capital Ltd and UBS Asset Management Switzerland AG.

For more information: https://www.slpet.co.uk/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.